Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832618 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06832618: Recruiting Phase 3 study of Atopic Dermatitis, sponsored by Incyte Corporation.
NCT06832618 is a Phase 3 study of Atopic Dermatitis that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 240 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06832618, a Phase 3 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Primary Outcome
Defined as achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI) score from baseline.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Vehicle Cream
Study Locations (20)
Georgia
- Lane Dermatology and Dermatologic Surgery - Columbus
- Cleaver Medical Group - Cumming
Illinois
- Sneeze Wheeze and Itch Associates Llc - Normal
- Endeavor Health Medical Group - Skokie
Michigan
- Oakland Hills Dermatology Pc - Auburn Hills
- Henry Ford Health System - Detroit
Missouri
- Red River Research Partners - Bolivar
- Medisearch Clinical Trials - Saint Joseph
Alabama
- Clinical Research Center of Alabama - Birmingham
Arizona
- Saguaro Dermatology - Phoenix
Colorado
- National Jewish Health - Denver
Florida
- Encore Medical Research, Llc Hollywood - Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2028-05-18 |
| Phase | Phase 3 |
What NCT06832618 shows while recruiting
NCT06832618 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT06832618 names 20 study sites across 16 states, led by Georgia, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06832618 about?
NCT06832618 is a clinical study titled "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis". The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
What is the current status of trial NCT06832618?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2025-06-17. Estimated completion is 2028-05-18.
What conditions does trial NCT06832618 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06832618?
The interventions under investigation include: Ruxolitinib (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT06832618?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832618 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06832618's enrollment target sits among peer trials
240 47th of 150 higher than 103 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI